SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer

Breast Cancer Research and Treatment

Volumn 137, Issue 1, 2013, Pages 213-223

  De Ronde, Jorma J ^a   Lips, Esther H ^a   Mulder, Lennart ^a   Vincent, Andrew D ^a   Wesseling, Jelle ^a   Nieuwland, Marja ^a   Kerkhoven, Ron ^a   Vrancken Peeters, Marie Jeanne T F D ^a   Sonke, Gabe S ^a   Rodenhuis, Sjoerd ^a   Wessels, Lodewyk F A ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

Biomarker; Breast cancer; Chemotherapy marker; Chemotherapy resistance; Neoadjuvant therapy; Response prediction

Indexed keywords

TUMOR MARKER;

AGTR1 GENE; ARTICLE; BEX1 GENE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; FEMALE; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; HUMAN; HUMAN TISSUE; LAPTM4B GENE; MAJOR CLINICAL STUDY; MARKER GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SERPINA6 GENE; SLC26A3 GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHLORIDE-BICARBONATE ANTIPORTERS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION; HUMANS; MEMBRANE PROTEINS; NEOADJUVANT THERAPY; NERVE TISSUE PROTEINS; ONCOGENE PROTEINS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ERBB-2; RNA, MESSENGER; TAXOIDS; TRANSCORTIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84871740744     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2340-x     Document Type: Article

References (32)

1. Ateeq B, Tomlins SA, Chinnaiyan AM (2009) AGTR1 as a therapeutic target in ER-positive and ERBB2-negative breast cancer cases. Cell Cycle 8(23):3794-3795
2. Borst P (2012) Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol 2(5):120066
3. Breitling R, Armengaud P, Amtmann A, Herzyk P (2004) Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 573(1-3):83-92
4. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105-113
5. de Ronde JJ, Rigaill G, Rottenberg S, Rodenhuis S, Wessels LFA Identifying subgroup markers in heterogeneous populations. Nucleic Acids Res (submitted)
6. Ghazoui Z, Buffa FM, Dunbier AK, Anderson H, Dexter T, Detre S, Salter J, Smith IE, Harris AL, Dowsett M (2011) Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer. Clin Cancer Res 17(9):3005-3012
7. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, Gottesman MM (2011) Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci USA 108(46):18708-18713
8. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacon JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF (2011) A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873-1881
9. Henley DE, Lightman SL (2011) New insights into corticosteroid-binding globulin and glucocorticoid delivery. Neuroscience 180:1-8
10. Iwamoto T, Lee JS, Bianchini G, Hubbard RE, Young E, Matsuoka J, Kim SB, Symmans WF, Hortobagyi GN, Pusztai L (2011) First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Res Treat 130(1):155-164
11. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, Bork P, von Mering C (2009) STRING 8 - a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 37(Database issue):D412-D416
12. Koziol JA (2010) Comments on the rank product method for analyzing replicated experiments. FEBS Lett 584(5):941-944
13. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC (2010) Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16(2):214-218
14. Li L, Wei XH, Pan YP, Li HC, Yang H, He QH, Pang Y, Shan Y, Xiong FX, Shao GZ, Zhou RL (2010) LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 29(43):5785-5795
15. Lian H (2008) MOST: detecting cancer differential gene expression. Biostatistics 9(3):411-418
16. Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S (2012) Neoadjuvant chemotherapy in ER+. Breast Cancer Res Treat 131(3):827-836
17. Lissner S, Nold L, Hsieh CJ, Turner JR, Gregor M, Graeve L, Lamprecht G (2010) Activity and PI3-kinase dependent trafficking of the intestinal anion exchanger downregulated in adenoma depend on its PDZ interaction and on lipid rafts. Am J Physiol Gastrointest Liver Physiol 299(4):G907-G920
18. Loo CE, Straver ME, Rodenhuis S, Muller SH, Wesseling J, Vrancken Peeters MJ, Gilhuijs KG (2011) Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 29(6):660-666
19. MacDonald JW, Ghosh D (2006) COPA - cancer outlier profile analysis. Bioinformatics 22(23):2950-2951
20. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229-235
21. Naderi A, Teschendorff AE, Beigel J, Cariati M, Ellis IO, Brenton JD, Caldas C (2007) BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer Res 67(14):6725-6736
22. Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K, Orrico AR, Dreher D, Walters R, Parker J, Hu Z, He X, Palazzo JP, Olopade OI, Szabo A, Perou CM, Bernard PS (2006) Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 8(2):R23
23. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T, Hess KR, Valero V, Booser D, Delorenzi M, Hortobagyi GN, Shi L, Symmans WF, Pusztai L (2010) Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 12(1):R5
24. Qureshi AC, Bahri A, Breen LA, Barnes SC, Powrie JK, Thomas SM, Carroll PV (2007) The influence of the route of oestrogen administration on serum levels of cortisol-binding globulin and total cortisol. Clin Endocrinol (Oxf) 66(5):632-635
25. Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE, Bhojani MS, Rehemtulla A, Kleer CG, Hayes DF, Lucas PC, Varambally S, Chinnaiyan AM (2009) AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci USA 106(25):10284-10289
26. Shimizu T, Sugiura T, Wakayama T, Kijima A, Nakamichi N, Iseki S, Silver DL, Kato Y (2011) PDZK1 regulates breast cancer resistance protein in small intestine. Drug Metab Dispos 39(11):2148-2154
27. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L (2010) Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 16(21):5351-5361
28. Tibshirani R, Hastie T (2007) Outlier sums for differential gene expression analysis. Biostatistics 8(1):2-8
29. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98(9):5116-5121
30. Venet D, Dumont JE, Detours V (2011) Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 7(10):e1002240
31. Wu B (2007) Cancer outlier differential gene expression detection. Biostatistics 8(3):566-575
32. Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8(3):151-160